Balancing Bleeding and Thrombosis in Lung Adenocarcinoma – JTH
Journal of Thrombosis and Haemostasis (JTH) shared a post on LinkedIn about a recent article by Thomas Fusillo et al. published in JTH, adding:
“Bleeding in patients with lung adenocarcinoma receiving concurrent administration of anticoagulation and VEGF or EGFR inhibitors
Clinicians often worry about combining anticoagulation with targeted cancer drugs.
In patients with lung adenocarcinoma, giving anticoagulants alongside VEGF or EGFR inhibitors was not associated with a statistically significant rise in major or clinically relevant non-major bleeding.
The data offer some reassurance for treating thrombosis in this group, though careful patient selection still applies.”
Title: Bleeding in patients with lung adenocarcinoma receiving concurrent administration of anticoagulation and vascular endothelial growth factor or epidermal growth factor receptor inhibitors
Authors: Thomas F. Fusillo, Avi Leader, Simon Mantha, Helen Ajufo, Andriy Derkach, Adam Schoenfeld, Rohan Singh, Peter Kaplinsky, Jeffrey I. Zwicker
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 4, 2026, 05:38Faizan Khan: Why Common Exposures Matter in VTE Risk
-
Sep 4, 2026, 04:56Marwa Mostafa: Microcytosis Is Not Always Iron Deficiency
-
Sep 4, 2026, 03:18Mukesh Kumar Maurya: Beyond ‘aPL Thrombosis’ – A Modern Approach to APS
-
Sep 4, 2026, 02:44Ahmed Kotb: Emergency Management of Critical Bleeding in ITP
-
Sep 4, 2026, 02:30Mario Jimenez: KDIGO 2026 – A More Proactive Approach to IV Iron in Hemodialysis
-
Sep 4, 2026, 02:18Edgardo Alania: Edoxaban in Intracranial Haemorrhage Survivors with AF
-
Sep 3, 2026, 20:33Jennifer Weinstein: Happy to Share Our New Work on the Patient Experience in VWD at the NBDF Conference
-
Sep 3, 2026, 20:31Guillaume Courbon: New Publication on Erythroid-Produced FGF23 and Its Role in Anemia
-
Sep 3, 2026, 20:30Phuong Khanh Morrow: FDA Approval Marks an Important Step Forward for the PV Community